Pharmacotherapy follow‐up of key points in the safety of oral antineoplastic agents
We assessed the impact of a pharmacotherapy follow‐up programme on key safety points [adverse events (AE) and drug administration] in outpatients treated with oral antineoplastic agents (OAA). We performed a comparative, interventional, quasi‐experimental study of outpatients treated with OAA in a S...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer care 2017-05, Vol.26 (3), p.e12463-n/a |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 3 |
| container_start_page | e12463 |
| container_title | European journal of cancer care |
| container_volume | 26 |
| creator | Escudero‐Vilaplana, V. Ribed, A. Romero‐Jimenez, R.M. Herranz‐Alonso, A. Sanjurjo‐Saez, M. |
| description | We assessed the impact of a pharmacotherapy follow‐up programme on key safety points [adverse events (AE) and drug administration] in outpatients treated with oral antineoplastic agents (OAA). We performed a comparative, interventional, quasi‐experimental study of outpatients treated with OAA in a Spanish hospital to compare pre‐intervention group patients (not monitored by pharmacists during 2011) with intervention group patients (prospectively monitored by pharmacists during 2013). AE data were collected from medical records. Follow‐up was 6 months, and 249 patients were included (pre‐intervention, 115; intervention, 134). After the first month, AE were detected in 86.5% of patients in the pre‐intervention group and 80.6% of patients in the intervention group, P = 0.096. During the remaining months, 79.0% patients had at least one AE in the pre‐intervention group compared with 78.0% in the intervention group, P = 0.431. AE were more prevalent with sorafenib and sunitinib. In total, 173 drug interactions were recorded (pre‐intervention, 80; intervention, 93; P = 0.045). Drug interactions were more frequent with erlotinib and gefitinib; food interactions were more common with sorafenib and pazopanib. Our follow‐up of cancer outpatients revealed a reduction in severe AE and major drug interactions, thus helping health professionals to monitor the safety of OAA. |
| doi_str_mv | 10.1111/ecc.12463 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1826650453</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1826650453</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3883-3ee616f9abdcacd4a805dd86833d75b36693918ccc0f3703f599e72e85b45d873</originalsourceid><addsrcrecordid>eNp10L1OwzAUBWALgWgpDLwAssQCQ1o7jh17RFH5kSrBQGfLdRyaksbBTlRl4xF4Rp4ElxYGJK6HO_jT0dUB4ByjMQ4zMVqPcZwwcgCGmDAaxYQmh2CIBMMRTWIyACferxDCBIvkGAxixtM45mwI5k9L5dZK23ZpnGp6WNiqspvP94-ugbaAr6aHjS3r1sOyhgFBrwrT9ts_61QFVd2WtbFNpXxbaqheTLCn4KhQlTdn-z0C89vpc3YfzR7vHrKbWaQJ5yQixjDMCqEWuVY6TxRHNM8544TkKV0QxgQRmGutUUFSRAoqhEljw-kioTlPyQhc7XIbZ98641u5Lr02VaXCSZ2XmMeMUZRQEujlH7qynavDdRILhGl4qQjqeqe0s947U8jGlWvleomR3HYtQ9fyu-tgL_aJ3WJt8l_5U24Akx3YlJXp_0-S0yzbRX4BpJGIng</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1901515179</pqid></control><display><type>article</type><title>Pharmacotherapy follow‐up of key points in the safety of oral antineoplastic agents</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Escudero‐Vilaplana, V. ; Ribed, A. ; Romero‐Jimenez, R.M. ; Herranz‐Alonso, A. ; Sanjurjo‐Saez, M.</creator><creatorcontrib>Escudero‐Vilaplana, V. ; Ribed, A. ; Romero‐Jimenez, R.M. ; Herranz‐Alonso, A. ; Sanjurjo‐Saez, M.</creatorcontrib><description>We assessed the impact of a pharmacotherapy follow‐up programme on key safety points [adverse events (AE) and drug administration] in outpatients treated with oral antineoplastic agents (OAA). We performed a comparative, interventional, quasi‐experimental study of outpatients treated with OAA in a Spanish hospital to compare pre‐intervention group patients (not monitored by pharmacists during 2011) with intervention group patients (prospectively monitored by pharmacists during 2013). AE data were collected from medical records. Follow‐up was 6 months, and 249 patients were included (pre‐intervention, 115; intervention, 134). After the first month, AE were detected in 86.5% of patients in the pre‐intervention group and 80.6% of patients in the intervention group, P = 0.096. During the remaining months, 79.0% patients had at least one AE in the pre‐intervention group compared with 78.0% in the intervention group, P = 0.431. AE were more prevalent with sorafenib and sunitinib. In total, 173 drug interactions were recorded (pre‐intervention, 80; intervention, 93; P = 0.045). Drug interactions were more frequent with erlotinib and gefitinib; food interactions were more common with sorafenib and pazopanib. Our follow‐up of cancer outpatients revealed a reduction in severe AE and major drug interactions, thus helping health professionals to monitor the safety of OAA.</description><identifier>ISSN: 0961-5423</identifier><identifier>EISSN: 1365-2354</identifier><identifier>DOI: 10.1111/ecc.12463</identifier><identifier>PMID: 26872286</identifier><language>eng</language><publisher>England: Hindawi Limited</publisher><subject>Administration, Oral ; Aftercare ; Aged ; Ambulatory Care - methods ; Analysis of Variance ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - adverse effects ; Antineoplastic drugs ; Cancer ; Chemotherapy ; Drug administration ; Drug Interactions ; education ; Female ; Food ; Gefitinib ; Humans ; Inhibitor drugs ; Intervention ; Male ; Medical personnel ; Medical records ; Middle Aged ; Neoplasms - drug therapy ; Nursing ; patient education ; patient information ; Patient Safety ; Patients ; Pharmacology ; Pharmacy Service, Hospital - methods ; Prospective Studies ; Remote Consultation ; Retrospective Studies ; Safety ; Side effects ; Socioeconomic Factors ; Spain ; Targeted cancer therapy ; therapy ; Young Adult</subject><ispartof>European journal of cancer care, 2017-05, Vol.26 (3), p.e12463-n/a</ispartof><rights>2016 John Wiley & Sons Ltd</rights><rights>2016 John Wiley & Sons Ltd.</rights><rights>Copyright © 2017 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3883-3ee616f9abdcacd4a805dd86833d75b36693918ccc0f3703f599e72e85b45d873</citedby><cites>FETCH-LOGICAL-c3883-3ee616f9abdcacd4a805dd86833d75b36693918ccc0f3703f599e72e85b45d873</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fecc.12463$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fecc.12463$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27902,27903,45552,45553</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26872286$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Escudero‐Vilaplana, V.</creatorcontrib><creatorcontrib>Ribed, A.</creatorcontrib><creatorcontrib>Romero‐Jimenez, R.M.</creatorcontrib><creatorcontrib>Herranz‐Alonso, A.</creatorcontrib><creatorcontrib>Sanjurjo‐Saez, M.</creatorcontrib><title>Pharmacotherapy follow‐up of key points in the safety of oral antineoplastic agents</title><title>European journal of cancer care</title><addtitle>Eur J Cancer Care (Engl)</addtitle><description>We assessed the impact of a pharmacotherapy follow‐up programme on key safety points [adverse events (AE) and drug administration] in outpatients treated with oral antineoplastic agents (OAA). We performed a comparative, interventional, quasi‐experimental study of outpatients treated with OAA in a Spanish hospital to compare pre‐intervention group patients (not monitored by pharmacists during 2011) with intervention group patients (prospectively monitored by pharmacists during 2013). AE data were collected from medical records. Follow‐up was 6 months, and 249 patients were included (pre‐intervention, 115; intervention, 134). After the first month, AE were detected in 86.5% of patients in the pre‐intervention group and 80.6% of patients in the intervention group, P = 0.096. During the remaining months, 79.0% patients had at least one AE in the pre‐intervention group compared with 78.0% in the intervention group, P = 0.431. AE were more prevalent with sorafenib and sunitinib. In total, 173 drug interactions were recorded (pre‐intervention, 80; intervention, 93; P = 0.045). Drug interactions were more frequent with erlotinib and gefitinib; food interactions were more common with sorafenib and pazopanib. Our follow‐up of cancer outpatients revealed a reduction in severe AE and major drug interactions, thus helping health professionals to monitor the safety of OAA.</description><subject>Administration, Oral</subject><subject>Aftercare</subject><subject>Aged</subject><subject>Ambulatory Care - methods</subject><subject>Analysis of Variance</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic drugs</subject><subject>Cancer</subject><subject>Chemotherapy</subject><subject>Drug administration</subject><subject>Drug Interactions</subject><subject>education</subject><subject>Female</subject><subject>Food</subject><subject>Gefitinib</subject><subject>Humans</subject><subject>Inhibitor drugs</subject><subject>Intervention</subject><subject>Male</subject><subject>Medical personnel</subject><subject>Medical records</subject><subject>Middle Aged</subject><subject>Neoplasms - drug therapy</subject><subject>Nursing</subject><subject>patient education</subject><subject>patient information</subject><subject>Patient Safety</subject><subject>Patients</subject><subject>Pharmacology</subject><subject>Pharmacy Service, Hospital - methods</subject><subject>Prospective Studies</subject><subject>Remote Consultation</subject><subject>Retrospective Studies</subject><subject>Safety</subject><subject>Side effects</subject><subject>Socioeconomic Factors</subject><subject>Spain</subject><subject>Targeted cancer therapy</subject><subject>therapy</subject><subject>Young Adult</subject><issn>0961-5423</issn><issn>1365-2354</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10L1OwzAUBWALgWgpDLwAssQCQ1o7jh17RFH5kSrBQGfLdRyaksbBTlRl4xF4Rp4ElxYGJK6HO_jT0dUB4ByjMQ4zMVqPcZwwcgCGmDAaxYQmh2CIBMMRTWIyACferxDCBIvkGAxixtM45mwI5k9L5dZK23ZpnGp6WNiqspvP94-ugbaAr6aHjS3r1sOyhgFBrwrT9ts_61QFVd2WtbFNpXxbaqheTLCn4KhQlTdn-z0C89vpc3YfzR7vHrKbWaQJ5yQixjDMCqEWuVY6TxRHNM8544TkKV0QxgQRmGutUUFSRAoqhEljw-kioTlPyQhc7XIbZ98641u5Lr02VaXCSZ2XmMeMUZRQEujlH7qynavDdRILhGl4qQjqeqe0s947U8jGlWvleomR3HYtQ9fyu-tgL_aJ3WJt8l_5U24Akx3YlJXp_0-S0yzbRX4BpJGIng</recordid><startdate>201705</startdate><enddate>201705</enddate><creator>Escudero‐Vilaplana, V.</creator><creator>Ribed, A.</creator><creator>Romero‐Jimenez, R.M.</creator><creator>Herranz‐Alonso, A.</creator><creator>Sanjurjo‐Saez, M.</creator><general>Hindawi Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FD</scope><scope>ASE</scope><scope>FPQ</scope><scope>FR3</scope><scope>K6X</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>201705</creationdate><title>Pharmacotherapy follow‐up of key points in the safety of oral antineoplastic agents</title><author>Escudero‐Vilaplana, V. ; Ribed, A. ; Romero‐Jimenez, R.M. ; Herranz‐Alonso, A. ; Sanjurjo‐Saez, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3883-3ee616f9abdcacd4a805dd86833d75b36693918ccc0f3703f599e72e85b45d873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Administration, Oral</topic><topic>Aftercare</topic><topic>Aged</topic><topic>Ambulatory Care - methods</topic><topic>Analysis of Variance</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic drugs</topic><topic>Cancer</topic><topic>Chemotherapy</topic><topic>Drug administration</topic><topic>Drug Interactions</topic><topic>education</topic><topic>Female</topic><topic>Food</topic><topic>Gefitinib</topic><topic>Humans</topic><topic>Inhibitor drugs</topic><topic>Intervention</topic><topic>Male</topic><topic>Medical personnel</topic><topic>Medical records</topic><topic>Middle Aged</topic><topic>Neoplasms - drug therapy</topic><topic>Nursing</topic><topic>patient education</topic><topic>patient information</topic><topic>Patient Safety</topic><topic>Patients</topic><topic>Pharmacology</topic><topic>Pharmacy Service, Hospital - methods</topic><topic>Prospective Studies</topic><topic>Remote Consultation</topic><topic>Retrospective Studies</topic><topic>Safety</topic><topic>Side effects</topic><topic>Socioeconomic Factors</topic><topic>Spain</topic><topic>Targeted cancer therapy</topic><topic>therapy</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Escudero‐Vilaplana, V.</creatorcontrib><creatorcontrib>Ribed, A.</creatorcontrib><creatorcontrib>Romero‐Jimenez, R.M.</creatorcontrib><creatorcontrib>Herranz‐Alonso, A.</creatorcontrib><creatorcontrib>Sanjurjo‐Saez, M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Technology Research Database</collection><collection>British Nursing Index</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Engineering Research Database</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of cancer care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Escudero‐Vilaplana, V.</au><au>Ribed, A.</au><au>Romero‐Jimenez, R.M.</au><au>Herranz‐Alonso, A.</au><au>Sanjurjo‐Saez, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacotherapy follow‐up of key points in the safety of oral antineoplastic agents</atitle><jtitle>European journal of cancer care</jtitle><addtitle>Eur J Cancer Care (Engl)</addtitle><date>2017-05</date><risdate>2017</risdate><volume>26</volume><issue>3</issue><spage>e12463</spage><epage>n/a</epage><pages>e12463-n/a</pages><issn>0961-5423</issn><eissn>1365-2354</eissn><abstract>We assessed the impact of a pharmacotherapy follow‐up programme on key safety points [adverse events (AE) and drug administration] in outpatients treated with oral antineoplastic agents (OAA). We performed a comparative, interventional, quasi‐experimental study of outpatients treated with OAA in a Spanish hospital to compare pre‐intervention group patients (not monitored by pharmacists during 2011) with intervention group patients (prospectively monitored by pharmacists during 2013). AE data were collected from medical records. Follow‐up was 6 months, and 249 patients were included (pre‐intervention, 115; intervention, 134). After the first month, AE were detected in 86.5% of patients in the pre‐intervention group and 80.6% of patients in the intervention group, P = 0.096. During the remaining months, 79.0% patients had at least one AE in the pre‐intervention group compared with 78.0% in the intervention group, P = 0.431. AE were more prevalent with sorafenib and sunitinib. In total, 173 drug interactions were recorded (pre‐intervention, 80; intervention, 93; P = 0.045). Drug interactions were more frequent with erlotinib and gefitinib; food interactions were more common with sorafenib and pazopanib. Our follow‐up of cancer outpatients revealed a reduction in severe AE and major drug interactions, thus helping health professionals to monitor the safety of OAA.</abstract><cop>England</cop><pub>Hindawi Limited</pub><pmid>26872286</pmid><doi>10.1111/ecc.12463</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0961-5423 |
| ispartof | European journal of cancer care, 2017-05, Vol.26 (3), p.e12463-n/a |
| issn | 0961-5423 1365-2354 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1826650453 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Administration, Oral Aftercare Aged Ambulatory Care - methods Analysis of Variance Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic drugs Cancer Chemotherapy Drug administration Drug Interactions education Female Food Gefitinib Humans Inhibitor drugs Intervention Male Medical personnel Medical records Middle Aged Neoplasms - drug therapy Nursing patient education patient information Patient Safety Patients Pharmacology Pharmacy Service, Hospital - methods Prospective Studies Remote Consultation Retrospective Studies Safety Side effects Socioeconomic Factors Spain Targeted cancer therapy therapy Young Adult |
| title | Pharmacotherapy follow‐up of key points in the safety of oral antineoplastic agents |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T09%3A53%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacotherapy%20follow%E2%80%90up%20of%20key%20points%20in%20the%20safety%20of%20oral%20antineoplastic%20agents&rft.jtitle=European%20journal%20of%20cancer%20care&rft.au=Escudero%E2%80%90Vilaplana,%20V.&rft.date=2017-05&rft.volume=26&rft.issue=3&rft.spage=e12463&rft.epage=n/a&rft.pages=e12463-n/a&rft.issn=0961-5423&rft.eissn=1365-2354&rft_id=info:doi/10.1111/ecc.12463&rft_dat=%3Cproquest_cross%3E1826650453%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1901515179&rft_id=info:pmid/26872286&rfr_iscdi=true |